Rimonabant is the first drug to be launched that selectively blocks CB1 receptors within the endocannabinoid system. They are located throughout the following areas of the body; brain, liver, adipose tissue (fat), gastrointestinal tract  (gut) and muscles. The messages sent by CB1 receptors help us to regulate energy levels by adjusting our need for food in relation to the level of energy used to perform bodily activities.     

It has been shown that using Rimonabant to affect CB1 receptors in this way can successfully suppress appetite and therefore aid weight loss. As is common with many medications, users of Rimonabant may experience some side effects whilst taking the drug. A list of recorded side effects is given below:

More commonly reported:

• nausea
• dizziness
• headache
• diarrhea

Less commonly reported:

• anxiety
• depressed mood
• depression
• vomiting
• insomnia
• paresthesia (pins and needles)
• tremor
• somnolence (drowsiness)
• amnesia
• disturbance in attention

Concerns have been raised by the EMDAC (Endocrinologic and Metabolic Drugs Advisory Committee) about the prevalence of cases of psychiatric disorders that occurred within members of the test study groups who were taking Rimonabant.  Notably, suicide was committed by two participants of the Rimonabant trials who had been taking the drug.